ZSNI-21 is a ADAM17/HDAC2 inhibitor with ADAM17 IC50 0.939 µM and HDAC2 IC50 0.844 µM. ZSNI-21 regulates the expression of apoptosis-related proteins (Bax, Bcl-2) and Cyclin D1, and induces apoptosis.. ZSNI-21 can be used for the research of hepatocellular carcinoma, breast cancer, and non-small cell lung cancer[1].